Agios Pharmaceuticals
AGIO
232 hedge funds and large institutions have $2.12B invested in Agios Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 81 reducing their positions, and 36 closing their positions.
620% more call options, than puts
Call options by funds: $127M | Put options by funds: $17.6M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
27% more capital invested
Capital invested by funds: $1.67B → $2.12B (+$452M)
2.54% more ownership
Funds ownership: 105.05% → 107.59% (+2.5%)
1% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 81
0% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 36
2% less funds holding
Funds holding: 237 → 232 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$71.8M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$42.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$23.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$14.9M |
| 5 |
BlackRock
New York
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$32.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$18.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$17.5M |
| 5 |
Jane Street
New York
|
-$12.4M |
AGIO Hedge Fund Activity: Q1 2026 in Review
232 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2026, worth a combined $2.12B — up 27% from $1.67B a quarter earlier.
Fund positioning in AGIO was balanced in Q1 2026: 36 funds opened new positions, 36 closed out, 82 added to existing stakes and 81 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $71.8M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $32.2M sold.
- 232 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2026, down from 237 in Q4 2025.
- Funds reported $2.12B of Agios Pharmaceuticals stock for Q1 2026, up 27% quarter-over-quarter.
- 36 funds opened new Agios Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of 0 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2026 was Lynx1 Capital Management, an estimated $71.8M added.
- The largest Agios Pharmaceuticals seller in Q1 2026 was TCG Crossover Management, an estimated $32.2M sold.
Based on aggregated 13F filings for Q1 2026.